



Unique PDX screening platform to rapidly progress anticancer agents

HuScreen+ is a unique *in vivo* screening platform utilizing a 1+1 study design to evaluate drug response using CrownBio's well-characterized patient-derived xenograft (PDX) collection.


Highlights of HuScreen+:

- Fast and efficient *in vivo* screening platform.
- Under 6-month turnaround time, utilizing live PDX models with proven robust growth.
- Reliable 1:1 study design enabling a cost effective way to screen many tumor types.
- Wide spectrum of tumor types with unique mutations, genetic features, and drug responses.

Additional Benefits:

Enable informed decision making on lead candidates and patient selection while reducing time to market.

- Evaluate anticancer agents
 - lead indication, positioning, and "go or no go" decision making
 - preclinical lead compound screening.
- Predict clinical resistance
 - develop strategies to overcome resistance.
- Leverage biomarker discovery.
- Guide and strategize your human clinical trial
 - e.g. combination strategies, dosing, 1st line vs 2nd line.



Contact Sales
US: +1.855.827.6968
UK: +44 (0)870 166 6234
busdev@crownbio.com

Schedule Scientific Consultation
Request a consultation to discuss your project.
consultation@crownbio.com

Explore Scientific Data
Log into HuBase™ to review PDX model data.
hubase.crownbio.com